Generating whole bacterial genome sequences of low-abundance species from complex samples with IMS-MDA by Seth-Smith, H M B et al.








Generating whole bacterial genome sequences of low-abundance species from
complex samples with IMS-MDA
Seth-Smith, H M B; Harris, S R; Scott, P; Parmar, S; Marsh, P; Unemo, M; Clarke, I N; Parkhill, J;
Thomson, N R
Abstract: The study of bacterial populations using whole genome sequencing is of considerable scientific
and clinical interest. However, obtaining bacterial genomic information is not always trivial: the target
bacteria may be difficult-to-culture or uncultured, and may be found within samples containing complex
mixtures of other contaminating microbes and/or host cells, from which it is very difficult to derive
robust sequencing data. Here we describe our procedure to generate sufficient target genomic DNA for
whole bacterial genome sequencing, from clinical samples of the difficult-to-culture, obligate intracellular
pathogen Chlamydia trachomatis, without the need for culture. Our protocol combines Immunomagnetic
Separation (IMS) for targeted bacterial enrichment with Multiple Displacement Amplification (MDA)
for whole genome amplification, followed by high throughput sequencing. Compared to other techniques
which might be used to generate such data, IMS-MDA is an inexpensive, low-technology and highly
transferable process, which provides amplified genomic DNA for sequencing from target bacteria in under
5 hours, with little hands-on time.
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The	  study	  of	  bacterial	  populations	  using	  whole	  genome	  sequencing	  is	  of	  considerable	  scientific	  2	  
and	  clinical	  interest.	  However,	  obtaining	  bacterial	  genomic	  information	  is	  not	  always	  trivial:	  the	  3	  
target	   bacteria	   may	   be	   difficult-­‐to-­‐culture	   or	   uncultured,	   and	   may	   be	   found	   within	   samples	  4	  
containing	  complex	  mixtures	  of	  other	  contaminating	  microbes	  and/or	  host	  cells,	  from	  which	  it	  is	  5	  
very	   difficult	   to	   derive	   robust	   sequencing	   data.	   Here	  we	   describe	   our	   procedure	   to	   generate	  6	  
sufficient	  target	  genomic	  DNA	  for	  whole	  bacterial	  genome	  sequencing,	  from	  clinical	  samples	  of	  7	  
the	  difficult-­‐to-­‐culture,	  obligate	  intracellular	  pathogen	  Chlamydia	  trachomatis,	  without	  the	  need	  8	  
for	   culture.	   Our	   protocol	   combines	   Immunomagnetic	   Separation	   (IMS)	   for	   targeted	   bacterial	  9	  
enrichment	  with	  Multiple	  Displacement	  Amplification	   (MDA)	   for	  whole	   genome	  amplification,	  10	  
followed	  by	  high	  throughput	  sequencing.	  Compared	  to	  other	  techniques	  which	  might	  be	  used	  to	  11	  
generate	  such	  data,	  IMS-­‐MDA	  is	  an	  inexpensive,	  low-­‐technology	  and	  highly	  transferable	  process,	  12	  
which	  provides	  amplified	  genomic	  DNA	   for	   sequencing	   from	   target	  bacteria	   in	  under	  5	  hours,	  13	  
with	  little	  hands-­‐on	  time.	  	  14	  




Driven	  by	  plummeting	  sequencing	  costs,	  whole	  genome	  sequencing	  has	  revolutionised	  the	  2	  
way	   we	   have	   been	   able	   to	   understand	   bacterial	   biology,	   pathogenesis,	   epidemiology,	  3	  
genetics	  and	  evolution.	   Sequencing	   technologies	  have	  been	  applied	   to	   track	   the	   temporal	  4	  
and	   geographic	   distribution	   of	   pathogens,	   and	   offer	   the	   precision	   to	   understand	   the	   true	  5	  
nature	  of	  infection	  within	  a	  single	  person	  1-­‐7.	  Much	  of	  our	  understanding	  of	  the	  nature	  and	  6	  
diversity	  of	  bacteria	  derives	  from	  species	  which	  can	  be	  easily,	  rapidly	  and	  selectively	  grown	  7	  
under	  laboratory	  conditions.	  It	  is	  a	  challenge	  to	  generate	  genomic	  DNA	  of	  sufficient	  quantity	  8	  
and	  quality	  for	  whole	  genome	  sequencing	  from	  uncultured,	  fastidious	  or	  difficult-­‐to-­‐culture	  9	  
bacteria.	  Discarded	  clinical	  samples	  represent	  an	  important	  resource	  for	  studying	  bacteria,	  10	  
although	   such	   samples	   may	   be	   complex,	   often	   containing	   low	   levels	   of	   the	   species	   of	  11	  
interest	  among	  a	  multitude	  of	  contaminating	  bacteria	  and	  host	  cells.	  	  12	  
We	   have	   developed	   an	   approach	   to	   enrich	   for	   specific	   bacteria	   and	   amplify	   sufficient	  13	  
genomic	  DNA	  for	  whole	  genome	  sequencing,	  directly	   from	  complex	  or	  non-­‐viable	  samples	  14	  
without	   the	   need	   for	   culture	   8.	   Our	  methodology	   combines	   Immunomagnetic	   Separation	  15	  
(IMS)	  with	  Multiple	  Displacement	  Amplification	  (MDA)	  and	  allows	  for	  access	  to	  the	  genomes	  16	  
of	   specific	  bacteria	  even	  where	   the	   target	   species	   is	   present	   at	   low	   levels	   and	  with	  other	  17	  
contaminating	  microbiota	   and	   host	   cells.	   To	   validate	   our	   methodology	   we	   amplified	   and	  18	  
sequenced	   complete	   genomes	   of	   C.	   trachomatis	   strains	   present	   in	   discarded	   clinical	  19	  
samples,	   representing	   the	   first	   time	   that	   whole	   bacterial	   genome	   sequences	   have	   been	  20	  
generated	  directly	  from	  uncultured	  clinical	  samples	  8.	  	  21	  
Chlamydia	  trachomatis	   is	  a	  pathogen	  of	  global	   importance,	  causing	  more	  than	  100	  million	  22	  
cases	  of	  sexually	   transmitted	  chlamydial	   infection	  annually	   9	  as	  well	  as	   the	  blinding	  ocular	  23	  
disease	  trachoma	  10.	  There	  are	  several	  subspecies-­‐level	  typing	  schemes	  for	  C.	  trachomatis,	  24	  
which	   group	   strains	   according	   to	   variation	   in	   the	   highly-­‐variable	   gene	   ompA,	   a	   panel	   of	  25	  
housekeeping	  genes	   (MLST)	   11-­‐13,	  or	   fast-­‐changing	   repetitive	   loci	   (variable	  number	   tandem	  26	  
repeats,	  VNTRs)	  14.	  However,	  these	  methods	  lack	  the	  resolution	  required	  for	  detailed	  strain	  27	  
tracking	   in	   the	   case	   of	   ompA-­‐genotyping	   and	  MLST,	   and	   can	   be	   vulnerable	   to	   stochastic	  28	  
change	  in	  the	  case	  of	  VNTRs.	  Moreover,	  recently	  it	  has	  been	  shown	  that	  recombination	  in	  C.	  29	  
trachomatis,	  leading	  to	  genetic	  exchange	  and	  diversification	  unlinked	  to	  phylogeny,	  severely	  30	  
limits	  the	  interpretation	  of	  data	  from	  these	  typing	  methodologies	  15-­‐17.	  For	  C.	  trachomatis,	  31	  
as	  for	  many	  other	  bacterial	  species,	  whole	  genome	  sequencing	  is	  the	  only	  technology	  that	  32	  
can	   provide	   the	   resolution	   required	   to	   determine	   true	   relationships,	   in	   addition	   to	   the	  33	  
accuracy	   and	   specificity	   required	   to	   differentiate	   closely	   related	   isolates	   typical	   of	  34	  
monomorphic	  species	  4.	  	  35	  
C.	   trachomatis	   is	   an	   ideal	   model	   bacterium	   for	   testing	   non-­‐culture	   based	   sequencing	  36	  
protocols:	  as	  an	  obligate	  intracellular	  pathogen	  it	  requires	  tissue	  culture	  for	  in	  vitro	  growth,	  37	  
a	  method	  which	  is	  technically	  challenging,	  expensive	  and	  time	  consuming;	  some	  strains	  may	  38	  
4	  
	  
be	   recalcitrant	   to	   culture;	   and	  discarded	  clinical	   samples	  are	  available	   for	   research.	  While	  1	  
deep-­‐sequencing	  of	  a	  clinical	  sample	  has	  been	  shown	  to	  be	  able	  to	  give	  some	  information	  2	  
about	  an	   infecting	  C.	   trachomatis	   strain18,	   this	  method	   is	  expensive	  and	   is	  not	   scalable	  or	  3	  
able	   to	   provide	   sufficient	   strain	   resolution.	   Several	   other	   technologies	   exist	   or	   are	   being	  4	  
developed	   for	   the	   depletion	   of	   host	   cells	   in	   clinical	   samples	   (including	   MolYsis	   Basic	   by	  5	  
Molzym	  and	  GeneRead	  Bacterial	  DNA	  Kit	  by	  Qiagen	   [not	  yet	   released]),	  particularly	  blood	  6	  
samples	  (discussed	  in	  19),	  but	  these	  are	  of	  less	  use	  when	  other	  microbiota	  are	  present	  in	  the	  7	  
sample,	   masking	   data	   from	   the	   bacterium	   of	   interest.	   Also	   of	   note	   are	   DNA	   target	  8	  
enrichment	  technologies,	  where	  the	  sequence	  of	  a	  reference	  strain	  can	  be	  used	  to	  develop	  9	  
baits	   covering	   the	  whole	  genome,	  allowing	   the	   specific	  hybridisation	  of	   the	   target	   strain’s	  10	  
DNA.	  Such	  methods	  have	  been	  shown	  to	  be	  effective	   in	  several	  studies	  on	  bacteriophage,	  11	  
bacteria	   and	   viruses	   19-­‐23	   and	   can	   be	   used	   on	   samples	   in	   lysis	   buffer,	   but	   they	   are	   highly	  12	  
expensive	  and	  time-­‐consuming,	  requiring	  the	  initial	  design	  and	  purchase	  of	  a	  custom	  array	  13	  
of	  baits.	  Additionally,	  if	  the	  species	  under	  study	  has	  a	  variable	  genome,	  not	  all	  the	  variation	  14	  
in	  the	  genome	  will	  be	  captured	  using	  these	  methods.	  	  15	  
The	  sequencing	  of	  genomes	  of	  single	  bacteria	  has	  been	  shown	  in	  several	  studies,	  isolated	  by	  16	  
micromanipulation,	  microfluidics	  or	  flow	  cytometry	  (reviewed	  in	  24,25).	  For	  some	  applications	  17	  
such	   as	   comparison	   of	   sequence	   variation	   between	   individual	   cells	   of	   the	   same	   species	  18	  
within	  a	  complex	  mix,	  methodologies	  such	  as	  these	  may	  offer	  some	  advantages,	  depending	  19	  
on	   the	   specific	   research	   goal.	   However,	   these	   techniques	   are	   highly	   time	   and	   resource	  20	  
consuming,	   with	   the	   isolation	   stages	   so	   far	   not	   targeted	   towards	   a	   particular	   bacterial	  21	  
species.	  Moreover	   it	   is	   very	  difficult	   to	   produce	   full	   coverage	  of	   the	   genomes	  of	   interest,	  22	  
which	  is	  an	  aim	  of	  our	  protocol,	  such	  that	  detailed	  genomic	  epidemiology	  can	  be	  performed.	  23	  
Further	  recent	  techniques	  include	  a	  “mini-­‐metagenome”	  approach	  following	  automated	  cell	  24	  
sorting,	  and	  growth	  of	  individual	  bacteria	  from	  communities	  within	  gel	  microdroplets	  prior	  25	  
to	  amplification	  26,27,	  from	  which	  better	  genome	  coverage	  is	  achieved	  as	  a	  larger	  number	  of	  26	  
bacteria	  are	  subject	  to	  amplification.	  	  27	  
The	   need	   for	   methods	   to	   target	   the	   genomes	   of	   difficult-­‐to-­‐culture	   bacteria	   was	   further	  28	  
demonstrated	   by	   a	   very	   recent	   paper28,	   in	   which	   IMS	   and	   MDA	   were	   also	   used	   in	  29	  
combination	   to	   sequence	   C.	   trachomatis	   genomes	   from	   clinical	   samples.	   This	   method	   is	  30	  
largely	   equivalent	   to	   the	   one	   detailed	   here,	   with	   similar	   antibodies	   employed,	   although	  31	  
alternative	   magnetic	   beads	   were	   used,	   a	   DNase	   step	   was	   included	   to	   reduce	   host	   DNA	  32	  
contamination	  (a	  step	  which	  we	  found	  did	  not	  increase	  the	  success	  rate),	  and	  an	  additional	  33	  
DNA	  extraction	  step	  was	  used	  prior	  to	  MDA.	  	  34	  
	  35	  
Development	  of	  the	  protocol	  36	  
IMS	   is	  an	  established	  technique	  for	  enriching	  target	  bacteria	   from	  complex	  mixtures	  using	  37	  
antibodies	  attached	  to	  magnetic	  beads.	  In	  the	  past,	  IMS	  has	  been	  used	  with	  varied	  samples,	  38	  
5	  
	  
in	  order	  to	  concentrate	  the	  target	  bacteria	  and	  remove	  inhibitors	  from	  the	  sample,	  enabling	  1	  
clearer	  and	  more	  accurate	  nucleic	  acid	  amplification-­‐based	  diagnosis	  29-­‐32.	  We	  chose	  to	  test	  2	  
IMS	  for	  bacterial	  enrichment	  prior	  to	  genome	  sequencing.	  3	  
Our	  experience	  of	  clinical	  swab	  samples	  for	  C.	  trachomatis	  diagnosis	  has	  shown	  that	  the	  vast	  4	  
majority	   of	   samples	  do	  not	   carry	   sufficient	   quantities	   of	   target	   bacteria	   and	   their	  DNA	   to	  5	  
allow	   genome	   sequencing	   from	   the	   sample	   either	   directly,	   or	   following	   amplification	   8.	  6	  
Consequently	  we	  chose	  to	  follow	  IMS	  with	  MDA	  which	  amplifies	  high	  molecular	  weight	  DNA	  7	  
using	  ø29	  polymerase	  and	  random	  hexamer	  primers	  33,34.	  This	  combined	  IMS-­‐MDA	  protocol	  8	  
can	   provide	   sufficient	   high	   quality	   genomic	   DNA	   for	   sequencing	   using	   high	   throughput	  9	  
technologies	   8.	   IMS-­‐MDA	   is	   a	   rapid,	   flexible,	   low-­‐technology,	   low	   cost	   (for	   consumable	  10	  
reagents,	  excluding	  quantification	  and	  sequencing	  costs)	  protocol	  with	  high	  potential	  for	  use	  11	  
with	  a	  multitude	  of	  sample	  types	  and	  bacterial	  species.	  12	  
	  13	  
Overview	  of	  IMS-­‐MDA	  14	  
The	  IMS-­‐MDA	  protocol	  is	  shown	  in	  Figure	  1	  and	  follows	  the	  following	  stages:	  1)	  Primary	  and	  15	  
magnetic	  bead-­‐conjugated	  secondary	  antibodies	  are	  mixed.	  2)	  After	  incubation,	  a	  magnet	  is	  16	  
used	   to	   retain	   the	  bound	  primary	  and	  secondary	  antibodies,	  and	  excess	  unbound	  primary	  17	  
antibody	   is	  removed.	  3)	  The	  bound	  antibodies	  are	  mixed	  with	  the	  clinical	  sample.	  4)	  After	  18	  
incubation,	  samples	  are	  washed	  to	  remove	  contaminating	  microbes	  and	  cells	  which	  are	  not	  19	  
bound	   to	   the	   antibodies.	   5)	   Enriched	   target	   cells	   are	   retained	   by	   a	   magnet.	   6)	   MDA	   is	  20	  
performed	  directly	  on	  the	  enriched	  bacterial	  sample.	  Subsequent	  to	  IMS-­‐MDA,	  the	  following	  21	  
steps	  are	  used	  to	  generate	  genome	  sequence	  data:	  7)	  The	  amplified	  DNA	  is	  quantified,	  and	  22	  
samples	   with	   sufficient	   target	   DNA	   are	   sequenced	   using	   a	   high	   throughput	   sequencing	  23	  
platform.	   8)	   Bioinformatic	   analysis	   is	   used	   to	   determine	   the	  quality	   of	   the	   sequence	  data	  24	  
and	  the	  nature	  of	  the	  targeted	  bacterial	  genome	  sequence.	  25	  
	  26	  
Applications	  of	  the	  method	  27	  
Our	   work	   focussed	   on	   obtaining	   complete	   genome	   sequences	   of	   the	   difficult-­‐to-­‐culture,	  28	  
sexually	  transmitted	  bacterium	  C.	  trachomatis	  8.	  The	  samples	  we	  first	  used	  to	  validate	  this	  29	  
approach	  were	  cultured	  and	  purified	  C.	  trachomatis,	  after	  which	  we	  tested	  the	  protocol	  on	  30	  
discarded	  urogenital	  swab	  samples	  that	  had	  returned	  a	  positive	  diagnosis	  for	  C.	  trachomatis	  31	  
by	  a	  routine	  diagnostic	  nucleic	  acid	  amplification	  test	  (NAAT)	  8,35.	  We	  have	  also	  successfully	  32	  
applied	   this	   technique	   to	  non-­‐viable	   archived	  C.	   trachomatis	   samples,	   providing	   access	   to	  33	  
historical	   genome	   data	   that	   would	   have	   otherwise	   been	   lost,	   as	   the	   samples	   contained	  34	  
insufficient	  DNA	  even	  for	  sequencing	  at	  high	  coverage	  levels,	  without	  prior	  enrichment.	  	  35	  
6	  
	  
We	  believe	  that	  the	  IMS-­‐MDA	  protocol	  would	  be	  equally	  applicable	  to	  any	  micro-­‐organism	  1	  
for	  which	  a	  suitable	  and	  specific	  primary	  antibody	  or	  aptamer	  exists	  or	  can	  be	  developed,	  2	  
and	  where	   suitable	   primary	   specimen	  material	   is	   available.	   The	   sample	  may	   be	   viable	   or	  3	  
non-­‐viable,	  as	  long	  as	  the	  bacterium	  remains	  intact	  such	  that	  the	  antigen	  remains	  associated	  4	  
with	  the	  genomic	  DNA.	  The	   low	  cost	  and	  high	  transportability	  of	   this	  Protocol	  means	  that	  5	  
samples	  can	  be	  prepared	  even	  in	  resource	  poor	  laboratories,	  and	  the	  critical	  first	  stages	  of	  6	  
IMS	   (stages	  1-­‐5	   in	  Figure	  1;	   1-­‐15	   in	   the	  Procedure)	   could	  even	  be	  performed	   in	   the	   field.	  7	  
IMS-­‐MDA	  has	  advantages	  over	  target	  enrichment	  techniques	  in	  situations	  when	  a	  reference	  8	  
genome	   sequence	   is	   not	   available,	   or	  when	   dealing	  with	   a	   highly	   variable	   genome,	   as	  de	  9	  
novo	  sequence	  assembly	  is	  possible	  using	  the	  sequence	  data	  generated	  by	  IMS-­‐MDA.	  10	  
	  11	  
Experimental	  design	  12	  
Sample	   choice.	  This	   technique	   is	   appropriate	   for	   samples	  which	  maintain	   intact	   bacteria.	  13	  
Our	   study	   used	   clinical	   samples	   placed	   directly	   into	  Chlamydia	   Transport	  Medium	   (CTM).	  14	  
Appropriate	  ethical	  permission	  may	  be	  required	  prior	  to	  work	  on	  clinical	  samples.	  In	  order	  15	  
to	  comply	  with	  the	  Human	  Tissue	  Act	   (2004)	  as	   it	  applies	   in	  England,	  Wales	  and	  Northern	  16	  
Ireland,	  human	  cells	  must	  be	  lysed	  on	  receipt	  and	  sequence	  data	  from	  patient	  DNA	  must	  be	  17	  
discarded	  prior	  to	  sequence	  analysis	  (see	  details	  in	  Materials).	  	  18	  
Clinical	   samples	  which	   involve	   swabs	  or	  urine	   samples	  placed	  directly	   into	   lysis	  buffer	  are	  19	  
not	  suitable	  for	  this	  approach.	  With	  the	  general	  move	  of	  molecular	  diagnostic	  laboratories	  20	  
towards	   the	  use	  of	   commercial	  NAATs	  which	  supply	  bespoke	  collection	  vessels	   containing	  21	  
lysis/stabilisation	   buffer,	   such	   as	   those	   for	   Gen-­‐Probe	   Aptima	   or	   Abbott	   m2000rt,	   future	  22	  
studies	  will	   generally	   require	   prospective	   additional	   samples	   to	   be	   taken	   and	   collected	   in	  23	  
suitable	   transport	   media	   as	   described	   above.	   Other	   possible	   samples	   could	   include	   any	  24	  
complex	   mixture	   with	   sufficient	   intact	   target	   material.	   Samples	   can	   be	   concentrated	   by	  25	  
centrifugation	  from	  larger	  volumes	  prior	  to	  resuspension	  in	  a	  suitable	  medium	  to	  keep	  the	  26	  
cells	  intact	  (e.g.	  transport	  medium	  or	  PBS),	  or	  homogenised	  if	  required.	  This	  method	  has	  so	  27	  
far	   been	   unsuccessful	   in	   generating	   complete	   genome	   sequences	   from	   urine	   samples,	  28	  
perhaps	  due	  to	  the	  condition	  of	  the	  bacteria.	  The	  minimum	  number	  of	  bacteria	  required	  for	  29	  
a	  successful	  outcome	  was	  difficult	   to	  precisely	  establish	  using	  C.	  trachomatis,	  which	   is	  not	  30	  
easily	   quantifiable,	   but	   a	   concentration	   dependent	   effect	   was	   observed	   during	   the	  31	  
validation	   of	   the	   procedure	   8.	   The	   affinity	   of	   the	   chosen	   antibody	   and	   the	   amount	   of	  32	  
contaminating	  material	  may	  also	  affect	  the	  required	  minimum	  input.	  33	  
Choice	  of	   antibody.	   Selection	  of	   an	   appropriate	   antibody	   is	   key	   for	   IMS-­‐MDA,	   as	   it	   is	   the	  34	  
critical	   component	   for	   the	   specific	   enrichment	   of	   the	   target	   organism.	   Bacterial	   surface	  35	  
antigens	   such	   as	   lipopolysaccharides	   (LPS)	   and	   outer	   membrane	   proteins	   are	   common	  36	  
antibody	   targets.	   Previously	   developed	   commercial	   diagnostic	   antibodies	   are	   excellent	  37	  
reagents	  for	  IMS,	  as	  they	  are	  likely	  to	  have	  been	  extensively	  tested	  for	  cross	  reactivity.	  For	  38	  
7	  
	  
our	  study	  we	  used	  the	  commercially	  available	  anti-­‐Chlamydia	  mouse	  IgG	  primary	  antibody	  1	  
(see	   Materials)	   which	   targets	   chlamydial	   LPS,	   present	   at	   approx.	   34,000	   molecules	   per	  2	  
bacterium	  36,	  and	  binds	  to	  all	  serovars	  of	  C.	  trachomatis.	  This	  reagent	  proved	  ideal	  since	  it	  is	  3	  
inexpensive	   for	   the	  quantities	  used,	  was	  originally	  developed	   for	  diagnostic	   purposes	   and	  4	  
thus	   has	   been	   tested	   for	   cross-­‐reactivity	   against	   many	   other	   microbial	   species	   possibly	  5	  
present	   in	   the	   urogenital	   tract	   including	   Lactobacillus	   lactis,	  Mycoplasma	   spp.,	   Neisseria	  6	  
gonorrhoeae	  and	  Gardnerella	  vaginalis	   (IMAGEN	  Chlamydia	  booklet37,38).	  We	  also	  tested	  a	  7	  
range	   of	   other	   anti-­‐Chlamydia	   antibodies	   which	   provided	   comparable	   results:	   mouse	  8	  
monoclonal	   IgG2b	   anti-­‐C.	   trachomatis	   LPS	   ,	  mouse	  monoclonal	   IgG2a	   anti-­‐C.	   trachomatis	  9	  
MOMP	   	   and	   rabbit	   polyclonal	   IgG	   anti-­‐C.	   trachomatis	   (see	   Materials).	   Similarly,	   small	  10	  
peptide	  aptamers	  that	  bind	  to	  specific	  target	  molecules	  could	  be	  used	  for	  this	  purpose.	  11	  
Magnetic	   bead	   selection.	   The	   primary	   antibodies	   can	   be	   attached	   to	   magnetic	   beads	  12	  
through	   use	   of	   specific	   secondary,	   magnetic	   bead-­‐conjugated	   antibodies,	   including	   anti-­‐13	  
mouse	  or	  anti-­‐rabbit	  IgG	  antibodies.	  The	  primary	  antibody	  used	  to	  validate	  this	  protocol	  is	  14	  
not	  directly	   linked	  to	  a	  magnetic	  bead	  and	  so	  we	  used	  a	  secondary	  anti-­‐mouse	   IgG	  sheep	  15	  
antibody.	  Alternatively,	  primary	  antibodies	  can	  be	  directly	  conjugated	  to	  activated	  magnetic	  16	  
beads	  (e.g.	  Dynabeads®	  MyOne™	  Carboxylic	  Acid,	  Invitrogen).	  	  17	  
Whole	  genome	  amplification.	  MDA	  was	  chosen	  as	  the	  most	  appropriate	  method	  for	  whole	  18	  
genome	   amplification	   (WGA).	   Since	   the	   development	   of	   this	   protocol,	   a	   new	  method	   of	  19	  
WGA	   has	   been	   developed:	   multiple	   annealing	   and	   looping-­‐based	   amplification	   cycles	  20	  
(MALBAC),	  which	   reduces	   the	  observed	  amplification	  bias	  of	   the	   isothermal	  MDA	  through	  21	  
cycles	   of	   primer	   extension	   39.	   While	   the	   resulting	   genome	   coverage	   may	   be	   more	   even,	  22	  
MALBAC	   currently	   produces	   more	   errors	   in	   nucleotide	   incorporation	   through	   the	   use	   of	  23	  
DNA	  polymerases	  with	   lower	   fidelity	   than	   the	  ø29	  polymerase.	   Therefore	  we	   continue	   to	  24	  
recommend	  the	  use	  of	  MDA.	  25	  
Bacterial	   genome	   quantitation	   by	   qPCR.	   A	   specific	   qPCR	   system	   is	   required	   to	   enable	  26	  
quantification	   of	   the	   target	   species’	   genomic	   DNA	   obtained	   by	   IMS-­‐MDA.	   Our	   initial	  27	  
experiments	  used	  a	  SYBR	  Green	  system,	  but	  greater	  accuracy,	  sensitivity	  and	  reproducibility	  28	  
was	   obtained	   with	   the	   Taqman®	   system	   described	   in	   Jalal	   et	   al.	   for	   C.	   trachomatis	   35,	  29	  
targeting	   the	   single	   copy	   chromosomal	   ompA	   gene.	   The	   information	   derived	   from	   qPCR	  30	  
directs	   the	   decision	   on	   which	   samples	   are	   suitable	   for	   downstream	   sequencing.	  31	  
Quantification	   of	   the	   total	   DNA	   resulting	   from	   the	   MDA	   reaction,	   which	   will	   include	  32	  
amplified	   DNA	   from	   contaminating	   organisms,	   is	   unnecessary	   and	   uninformative	   for	   our	  33	  
purpose.	  For	  C.	  trachomatis,	  we	  found	  that	  a	  minimum	  of	  1,500,000	  genome	  copies	  per	  µl	  34	  
was	  required	  to	  provide	  complete	  genome	  sequences	  with	  confidence	  in	  single	  nucleotide	  35	  
polymorphisms	  (SNP)	  calling.	  36	  
Controls.	  Fresh	  buffer	  can	  be	  used	  as	  a	  negative	  control	  for	  contamination	  and	  be	  processed	  37	  
in	   parallel	   with	   experimental	   samples,	   although	   we	   had	   never	   found	   contamination	   to	  38	  
occur.	  Buffer	  containing	  the	  target	  organism	  can	  be	  used	  as	  a	  positive	  control,	   if	  available.	  39	  
8	  
	  
Positive	  and	  negative	  controls	  for	  MDA	  are	  described	  with	  the	  manufacturer’s	  instructions.	  1	  
The	  final	  result	  is	  determined	  as	  being	  positive	  or	  negative	  after	  analysis	  of	  the	  sequencing	  2	  
data.	  3	  
Genome	  sequencing.	  We	  used	  Illumina	  GAII	  and	  HiSeq	  platforms	  in	  our	  study,	  but	  the	  DNA	  4	  
produced	  should	  be	  equally	  amenable	  to	  other	  sequencing	  technologies.	  For	  SNP	  analysis,	  5	  
high-­‐throughput	  technologies	  such	  as	  Illumina	  or	  Ion	  Torrent	  are	  recommended	  because	  of	  6	  
their	   high	   and	   accurate	   sequence	   yield	   per	   sequencing	   run.	  We	   have	   used	   high	   levels	   of	  7	  
multiplexing	  (up	  to	  96)	  with	  IMS-­‐MDA	  samples	  with	  no	  deleterious	  effects.	  8	  
Data	  analysis.	  We	  mapped	  the	  sequence	  data	  to	  a	  known	  reference	  genome	  to	  determine	  9	  
the	   extent,	   depth	   and	   evenness	   of	   coverage.	   This	   was	   performed	   using	   SMALT	  10	  
(http://www.sanger.ac.uk/resources/software/smalt/),	   although	   similar	   programs	   are	  11	  
available	  including	  bwa	  and	  SOAP	  40,41.	  Using	  our	  experimental	  design,	  bases	  and	  SNPs	  can	  12	  
be	  called	  with	  accuracy	  when	  the	  mean	  depth	  of	  coverage	  is	  greater	  than	  35×,	  as	  long	  as	  the	  13	  
coverage	  coefficient	  of	  variation	  (CV	  =	  standard	  deviation/mean)	  is	  not	  greater	  than	  1.	  MDA	  14	  
can	  produce	  uneven	  coverage,	  and	  with	  CV	  values	  >0.5	  manual	  checking	  of	  base	  calling	   is	  15	  
recommended.	  The	  C.	  trachomatis	  genome	  is	  extremely	  stable	  in	  terms	  of	  gene	  content	  and	  16	  
overall	  genome	  architecture	  16,42-­‐45,	  meaning	  that	  mapping-­‐based	  approaches	  allowed	  us	  to	  17	  
accurately	   reconstruct	  more	   than	  99%	  of	   the	  genome	  of	   samples	  meeting	   these	  coverage	  18	  
criteria.	   For	  other	  bacteria,	  where	   the	  genome	  may	   contain	   accessory	   regions	   that	  would	  19	  
not	  be	  accessible	  by	  mapping-­‐based	  methods,	  de	  novo	  assembly	  would	  be	  required.	  In	  such	  20	  
cases	   it	   is	   important	   to	   note	   that	   many	   assembly	   algorithms	   make	   the	   assumption	   of	  21	  
relatively	   constant	   read-­‐coverage	   levels	   across	   the	   sequenced	   genome,	   and	  may	   produce	  22	  
poor	  results	  when	  used	  with	  sequence	  reads	  from	  samples	  that	  have	  been	  subject	  to	  IMS-­‐23	  
MDA.	  We	   successfully	   assembled	   large	   contigs	   from	   C.	   trachomatis	   IMS-­‐MDA	   data	   using	  24	  
SPAdes	  46,	  an	  assembly	  program	  designed	  for	  use	  with	  sequence	  reads	  from	  MDA-­‐amplified	  25	  
single-­‐cell-­‐derived	   DNA.	   For	   de	   novo	   assembly	   of	   IMS-­‐MDA	   data	   we	   would	   therefore	  26	  
recommend	  use	  of	  an	  algorithm	  designed	   for	   sequence	  data	   from	  amplified	  DNA,	  such	  as	  27	  
velvet-­‐sc	   47,	   IDBA-­‐UD	   48	   or	   SPAdes	   46.	   These	   programs	   also	   account	   for	   chimeric	   DNA	  28	  
rearrangements	  that	  may	  occur	  during	  MDA,	  and	  which	  again	  may	  confound	  analyses	  with	  29	  
assembly	   programs	  not	   designed	   for	   this	   specific	   purpose.	   In	   order	   to	   remove	   assembled	  30	  
regions	   derived	   from	   contaminating	   DNA,	   we	   aligned	   the	   resulting	   contigs	   against	   a	  31	  
reference	  C.	  trachomatis	  genome	  sequence	  using	  abacas	  49.	  This	  process	  is	  enabled	  by	  the	  32	  
extremely	  conserved	  nature	  of	  the	  C.	  trachomatis	  genome	  and	  allows	  the	  identification	  and	  33	  
resolution	  of	  inverted	  repeats,	  which	  may	  otherwise	  result	  in	  artefacts	  during	  assembly.	  The	  34	  
resulting	  C.	  trachomatis	  genomes	  in	  our	  study	  were	  finally	  assembled	  into	  2	  –	  21	  contigs	  8.	  35	  
We	   were	   also	   able	   to	   identify	   one	   mixed	   infection	   within	   the	   samples	   tested,	   and	   to	  36	  
separate	   out	   the	   sequences	   of	   both	   strains	   based	   on	   the	   relative	   coverage	   of	   the	   two	  37	  




Limitations	  of	  the	  method	  1	  
IMS-­‐MDA	  allows	  access	  to	  the	  genomic	   information	   in	  otherwise	   inaccessible	  samples	  and	  2	  
our	  studies	  have	  shown	  that	  we	  can	  generate	  accurate	  whole	  genome	  sequences	  from	  15-­‐3	  
30%	   of	   discarded	   clinical	   swab	   samples	   that	   have	   tested	   positive	   by	   a	   routine	   diagnostic	  4	  
NAAT	   8.	   The	   reasons	   for	   lack	  of	   success	   in	   some	  samples	   is	  unclear,	  but	  was	  unrelated	   to	  5	  
choice	   of	   antibody	   or	   incubation	   conditions.	   Therefore	   it	   is	   assumed	   that	   the	   load	   of	   the	  6	  
target	  bacterium	  and	  the	  integrity	  of	  the	  sample	  are	  keys	  to	  the	  success	  of	  the	  technique.	  7	  
Clearly	  samples	  in	  which	  the	  genomic	  DNA	  is	  dissociated	  from	  the	  targeted	  antigen	  will	  not	  8	  
provide	  sufficient	  DNA	  of	   interest	  to	  sequence.	  Careful	  selection	  of	  samples	   is	  essential	   to	  9	  




REAGENTS	  	  2	  
NaH2PO4xH2O	  (Sigma-­‐Aldrich,	  cat.	  no.	  S9638)	  	  	  3	  
Na2HPO4x2H2O	  (Sigma-­‐Aldrich,	  cat.	  no.	  S3264)	  	  	  4	  
NaCl	  (Sigma-­‐Aldrich,	  cat.	  no.	  S3014)	  	  	  5	  
Tween	  20®	  (Sigma-­‐Aldrich,	  cat.	  no.	  P9416)	  	  	  6	  
Primary	  antibodies:	   IMAGEN	  Chlamydia	   (Oxoid,	  ThermoFisher,	  cat.	  no.	  K610111-­‐2),	  mouse	  7	  
monoclonal	   anti-­‐C.	   trachomatis	   LPS	   IgG2b	   (MyBioSource,	   clone	   no.	   M4020310),	   mouse	  8	  
monoclonal	  anti-­‐C.	  trachomatis	  MOMP	  IgG2a	  (AbCam,	  Cambridge,	  UK,	  clone	  no.	  BIOD166)	  9	  
and	  rabbit	  polyclonal	  anti-­‐C.	  trachomatis	  IgG	  (MyBioSource,	  San	  Diego,	  California,	  USA,	  cat.	  10	  
no.	  MBS221885)	  	  11	  
Dynabeads®	   M-­‐280	   Sheep	   Anti-­‐Mouse	   IgG	   (Invitrogen,	   cat.	   no.	   11201D)	   or	   other	  12	  
appropriate	  secondary	  antibody-­‐coupled	  or	  activated	  Dynabeads®.	  13	  
illustra	  GenomiPhi	  V2	  DNA	  Amplification	  Kit	  (GE	  Healthcare,	  cat.	  no.	  25-­‐6600-­‐30)	  or	  RepliG	  14	  
(Qiagen,	  cat.	  no.	  150023)	  	  15	  
Clinical	   samples.	   We	   obtained	   discarded	   urogenital	   clinical	   samples	   in	   Remel	   M4RT	  16	  
transport	   medium	   (ThermoFisher).	   !CAUTION	   Appropriate	   ethical	   permission	   might	   be	  17	  
required	   for	   the	   use	   of	   discarded	   clinical	   samples.	   Our	   study	   was	   approved	   by	   the	  18	  
appropriate	   National	   Research	   Ethics	   Service	   Committee.	   Additionally,	   we	   automatically	  19	  
mapped	  all	   sequence	  reads	  to	  the	  human	  genome	  directly	  after	   the	  sequence	  generation,	  20	  
and	  discarded	  human	  sequence	  data	  without	  further	  analysis.	   !	  CAUTION:	  Clinical	  samples	  21	  
will	   very	   likely	   contain	   viable	   bacteria,	   therefore	   samples	   should	   be	   handled	   under	  22	  
appropriate	   containment	   conditions	   (for	   C.	   trachomatis	   under	   containment	   level	   2,	  23	  
preferably	  in	  a	  class	  2	  biological	  safety	  cabinet)	  until	  the	  bacteria	  have	  been	  heat-­‐killed.	  	  24	  
TaqMan®	  Fast	  Advanced	  Master	  Mix	  (Applied	  Biosystems,	   Invitrogen,	  cat.	  no.	  4444556)	  or	  25	  
alternative	  qPCR	  reagents.	  26	  
qPCR	   primers	   and	   probes.	   Ideally	   the	   qPCR	   target	   should	   be	   a	   single-­‐copy	   locus	   on	   the	  27	  
bacterial	   chromosome.	   The	   largest	   chromosome	   should	  be	   targeted	   if	   there	   is	  more	   than	  28	  
one	   in	   the	   bacterium	   of	   interest	   as	   MDA	   amplifies	   smaller	   circular	   molecules	   such	   as	  29	  
plasmids	  to	  higher	  copy	  numbers	  than	   larger	  molecules.	   If	  no	  genomic	   information	  on	  the	  30	  
bacterium	  exists,	  it	  could	  be	  attempted	  to	  target	  specific	  16S	  rRNA	  gene	  sequences.	  For	  C.	  31	  
trachomatis	   quantification,	   we	   used	   the	   Taqman	   primer	   set	   targeting	   the	   chromosomal	  32	  
single	  copy	  ompA	   gene	  F	  primer	  HJ-­‐MOMP-­‐1:	  5’	  GACTTTGTTTTCGACCGTGTT,	  R	  primer	  HJ-­‐33	  
11	  
	  
MOMP-­‐2:	   5’	   ACARAATACATCAAARCGATCCCA,	   probe	   MOMP:	   5’	   VIC-­‐1	  
ATGTTTACVAAYGCYGCTT	  35	  (Sigma	  Aldrich	  custom	  oligos).	  	  	  2	  
	  3	  
	  4	  
EQUIPMENT	  	  5	  
DynaMag™-­‐2	  Magnet	  (Invitrogen,	  cat.	  no.	  12321D).	  	  6	  
Shaking	   incubator	   (Innnova	  42,	  New	  Brunswick	  Scientific,	  Eppendorf,	  cat.	  no.	  M1335-­‐0002	  7	  
or	  equivalent)	  or	  platform	  rocker	  (STR6,	  Stuart	  Scientific,	  ScienceLab.com,	  cat.	  no.	  65-­‐286-­‐8	  
674	  or	  equivalent).	  A	  tube	  rotator	  can	  also	  be	  used	  (SB2	  with	  SB3/	  1,	  Stuart	  Scientific,	  cat.	  9	  
no.	  SB2	  and	  SB3/1	  or	  equivalent).	  10	  
Microcentrifuge	  (Eppendorf	  5418,	  cat.	  no.	  FA-­‐45-­‐18-­‐11	  or	  equivalent).	  11	  
2	  ml	  Safe-­‐lock	  tubes™	  (Eppendorf,	  cat.	  no.	  0030	  120.094).	  12	  
Vortex	  (Vortex-­‐Genie	  2,	  Scientific	  Industries,	  cat.	  no.	  SI-­‐0266	  or	  equivalent).	  13	  
PCR	  tubes	  or	  plates	  and	  sealer,	  0.2	  ml	  (Thin-­‐walled	  dome-­‐capped	  strips,	  Thermo	  Scientific,	  14	  
cat.	   no.	   AB	   -­‐0451,	   Eppendorf	   Twin.tec,	   Eppendorf,	   cat.	   no.	   0030133374	   and	  Microseal	   A	  15	  
film,	  BioRad,	  cat	  no.	  MSA5002	  or	  equivalent).	  16	  
PCR	  machine	  (e.g.	  MJ	  Research	  Tetrad	  2	  DNA	  Engineer	  cycler,	  Bio-­‐Rad,	  cat.	  no.	  PTC–0240G).	  17	  
Real-­‐time	   quantitative	   PCR	  machine	   (StepOne™	  Real-­‐Time	   PCR	   System,	   Life	   Technologies,	  18	  
Invitrogen,	  cat.	  no.	  4376600,	  or	  equivalent).	  19	  
MicroAmp	  Fast	  Optical	  96	  well	  qPCR	  plate	  (Applied	  Biosystems,	  cat.	  no.	  4311971).	  20	  
MicroAmp	  Fast	  Optical	  adhesive	  film	  (Applied	  Biosystems,	  cat.	  no.	  4346906).	  21	  
Where	   required:	   class	   2	   biological	   safety	   cabinet	   for	   handling	   clinical	   samples	   or	   other	  22	  
samples	  which	  may	  contain	  live	  containment	  level	  2	  organisms.	  23	  
	  24	  
REAGENT	  SETUP	  25	  
Isotonic	  PBS.	  Mix	  0.16	  g/l	  NaH2PO4xH2O,	  0.98	  g/l	  Na2HPO4x2H2O,	  8.10	  g/l	  NaCl;	   autoclave	  26	  
and	  aliquot	  into	  sterile	  100	  ml	  bottles.	  	  27	  
PBST	   (PBS-­‐Tween)	  wash	  buffer.	  Add	  Tween	  20®	   to	   isotonic	  PBS	   to	  0.05%	  vol/vol.	   Prepare	  28	  
fresh	  before	  use.	  CRITICAL:	  Lack	  of	  Tween	  20	  in	  the	  wash	  buffer	  can	  cause	  clumping	  of	  the	  29	  
beads	  and	  lower	  the	  efficacy	  of	  the	  procedure.	  30	  
12	  
	  
qPCR	  standards.	  Serially	  diluted	  standards	  should	  be	  used	  alongside	  experimental	  samples	  1	  
for	  approximating	  the	  number	  of	   target	  organism	  genome	  copies.	  For	  this	  purpose,	  either	  2	  
use	   a	   known	   quantity	   of	   pure	   genomic	   DNA	   or,	   where	   necessary,	   generate	   purify	   and	  3	  
quantify	   a	   PCR	   product	   	   covering	   the	   locus	   targeted	   by	   the	   qPCR	   assay.	   For	   the	   C.	  4	  
trachomatis	  ompA	  Taqman	  assay	  we	  generated	  a	  standard	  PCR	  products	  using	  the	  primers	  f:	  5	  
5’-­‐CGGAATTGTGCATTTACGTG3’;	  r:	  5’-­‐CTACGCTGAGGACGGTAAGC3’.	  6	  
	   	  7	  
Helena  30.8.13 12:33
Kommentar [1]: No,	  this	  is	  a	  one	  off,	  making	  
and	  diluting	  the	  standards.	  I	  would	  consider	  it	  part	  




	  	  IMS	  of	  bacteria	  from	  complex	  samples	  –	  TIMING	  minimum	  2.5h	  2	  
CRITICAL	  This	  protocol	  can	  be	  used	  to	  process	  between	  1	  and	  16	  samples	  simultaneously.	  3	  
For	   each	   sample	   to	   be	   processed,	   use	   2	   µl	   of	   Dynabeads®.	   Beads	   for	   all	   samples	   are	  4	  
prepared	  in	  one	  pool	  in	  steps	  1-­‐9,	  prior	  to	  aliquotting	  them	  to	  the	  individual	  samples.	  5	  
1 Vortex	   the	   stock	  of	  Dynabeads®,	   remove	   the	   required	   volume	  and	  place	   in	   a	  2	  ml	  6	  
tube.	  	  7	  
2 Add	  0.5	  ml	  PBST	  and	  resuspend	  the	  beads	  with	  a	  1	  sec	  vortex	  or	  by	  flicking	  the	  tube.	  8	  
Place	  the	  tube	   in	  the	  DynaMag™-­‐2	  Magnet	  and	   leave	  for	  2	  min.	  Remove	  the	   liquid	  9	  
while	  the	  tube	  is	  still	  held	  in	  the	  magnet,	  retaining	  the	  Dynabeads®	  in	  the	  tube.	  10	  
?	  TROUBLESHOOTING	  11	  
3 Remove	  the	  tube	  from	  the	  magnet	  and	  repeat	  step	  2.	  12	  
4 Remove	  the	  tube	  from	  the	  magnet	  and	  add	  0.5	  ml	  PBST.	  Per	  sample	  to	  be	  processed,	  13	  
add	  primary	  antibody	  to	  the	  equivalent	  of	  approx.	  1012	  IgG	  molecules	  (e.g.	  0.25	  µl	  of	  14	  
IMAGEN	  Chlamydia	  per	  sample).	  15	  
5 Incubate	  the	  beads	  at	  20oC	  shaking	  at	  200	  rpm	  for	  at	  least	  1	  h.	  Note	  that	  we	  observe	  16	  
no	  decrease	   in	  performance	  using	  temperatures	   in	   the	  range	  of	  4-­‐30oC,	   incubation	  17	  
time	   of	   up	   to	   24	   h,	   or	   with	   alternative	   mixing	   methods	   including	   rotation	   and	  18	  
rocking.	  19	  
6 During	  the	  incubation,	  prepare	  the	  clinical	  samples	  by	  defrosting	  them	  if	  necessary.	  20	  
!CAUTION	   Samples	   containing	   live	   bacteria	   must	   be	   handled	   under	   appropriate	  21	  
containment	  conditions	  (see	  Materials).	  22	  
7 Perform	  a	  pulse	  spin	  in	  the	  microcentrifuge	  on	  the	  tube	  from	  Step	  5.	  23	  
8 Place	  the	  tube	  in	  the	  magnet	  and	  leave	  for	  2	  min.	  Remove	  the	  liquid	  while	  the	  tube	  24	  
is	  still	  held	  in	  the	  magnet,	  retaining	  the	  Dynabeads®	  in	  the	  tube.	  25	  
9 To	  remove	  any	  unbound	  primary	  antibody	  from	  the	  solution,	  perform	  step	  2	  twice	  26	  
and	  resuspend	  in	  50	  µl	  PBST	  per	  sample	  to	  be	  processed.	  27	  
10 Place	  aliquots	  of	  the	  clinical	  samples	  (10-­‐200	  µl	  depending	  on	  the	  available	  volume)	  28	  
in	   2	  ml	   tubes.	   Add	   50	  µl	   of	   the	   antibody-­‐bound	  Dynabeads®	   from	   Step	   9	   to	   each	  29	  
sample	  and	  mix	  by	  flicking	  the	  tubes.	  30	  
?	  TROUBLESHOOTING	  31	  
11 Perform	  step	  5.	  32	  
12 Perform	  a	  pulse	  spin	  on	  the	  tubes.	  33	  
13 Place	  the	  tubes	  in	  the	  magnet	  and	  leave	  for	  2	  min.	  Remove	  the	  liquid	  while	  the	  tubes	  34	  
are	  still	  held	  in	  the	  magnet,	  retaining	  the	  Dynabeads®	  in	  the	  tubes.	  35	  
?	  TROUBLESHOOTING	  36	  
14 To	  remove	  contaminating	  material	  from	  the	  target	  bacteria,	  perform	  Step	  2	  twice.	  37	  
14	  
	  
15 After	  the	  final	  wash	  remove	  as	  much	  of	  the	  wash	  buffer	  as	  possible,	  leaving	  just	  the	  1	  
Dynabeads®	  in	  the	  tubes.	  2	  
PAUSE	   POINT	  Material	   can	   be	   stored	   at	   -­‐20oC	   for	   at	   least	   14	   days	   prior	   to	   amplification.	  3	  
Material	   can	   be	   transported	   at	   this	   stage.	   To	   inactivate	   biological	  material	   for	   transport,	  4	  
samples	   can	   be	   heated	   to	   95oC	   for	   5	   min	   and	   subsequently	   stored	   at	   -­‐20oC	   for	   several	  5	  
months.	  6	  
	  	  MDA	  –	  TIMING	  2.5	  h	  7	  
16 Perform	   MDA	   using	   the	   illustra	   GenomiPhi	   V2	   DNA	   Amplification	   Kit.	   Resuspend	  8	  
each	  of	  the	  Dynabeads®	  pellets	  from	  Step	  15,	  which	  carry	  the	  template	  DNA,	  in	  9	  µl	  9	  
sample	   buffer,	   and	   transfer	   the	   full	   volume	   to	   a	   0.2	   ml	   well	   of	   a	   PCR	   plate.	   The	  10	  
Dynabeads®	  can	  remain	  in	  the	  samples	  throughout	  the	  reaction.	  	  11	  
17 Complete	   the	   MDA	   according	   to	   the	   manufacturer’s	   instructions,	   using	   the	   95oC	  12	  
denaturation	  step	  to	  release	  DNA	  from	  the	  bacteria.	  13	  
DNA	   Quantification	   and	   Genome	   Sequencing	   –	   TIMING	   several	   days	   up	   to	   weeks,	  14	  
depending	  on	  method	  used	  15	  
18 Quantify	   the	   amount	   of	   target	   bacterium	   DNA	   produced	   by	   performing	   Taqman	  16	  
qPCR.	  Make	  sufficient	  master	  mix	  for	  the	  required	  number	  of	  samples	  and	  standards	  17	  
using	  TaqMan®	  Fast	  Advanced	  Master	  Mix	  in	  a	  reaction	  volume	  of	  20	  µl,	  with	  each	  18	  
primer	  at	  a	  final	  concentration	  of	  300nM	  and	  probe	  at	  final	  concentration	  of	  150nM.	  19	  
19 Add	  1	  µl	  of	  each	  sample	  from	  Step	  17	  to	  19	  µl	  of	  master	  mix,	  in	  a	  96	  well	  qPCR	  plate	  20	  
and	  seal	  with	  adhesive	  film.	  	  21	  









Denature Anneal / Extend 
1 50 °C, 2 min 95 °C, 20 s    
2–41   95 °C, 1 s 60 °C, 20s 
	  24	  
21 Analyse	  the	  results	  in	  the	  qPCR	  software,	  using	  the	  cycle	  threshold	  (Ct)	  values	  from	  25	  
the	  standards	  to	  calculate	  the	  amount	  of	  target	  DNA	  in	  the	  IMS-­‐MDA	  samples.	  26	  
?	  TROUBLESHOOTING	  27	  
CRITICAL	   STEP	   For	   obtaining	   complete,	   accurate	   bacterial	   genome	   sequences,	  28	  
>1,500,000	   genome	   copies	   per	  µl	   are	   required	   (data	   from	   C.	   trachomatis).	   Minimum	  29	  
Helena  30.8.13 12:59
Kommentar [2]: This	  is	  really	  going	  to	  depend	  
on	  the	  software	  used.	  In	  the	  StepOne	  software,	  the	  
values	  are	  automatically	  calculated	  for	  standards	  
and	  samples,	  and	  given	  for	  each	  sample,	  which	  is	  
why	  I	  haven’t	  elaborated.	  
Zlotorynski, Eytan   30.8.13 10:41
Kommentar [3]: Au,	  this	  is	  the	  Step	  to	  explain	  
(see	  also	  comment	  3):	  Please	  explain	  the	  parameter	  
to	  be	  recorded	  in	  the	  genomic/dilution	  standards	  
qPCR	  reactions,	  and	  instruct	  to	  prepare	  a	  function	  
from	  all	  the	  standards	  against	  which	  the	  
experimental	  samples	  can	  be	  quantified.	  
15	  
	  
requirement	  for	  other	  bacteria	  and	  samples	  should	  be	  empirically	  determined.	  	  It	  is	  not	  1	  
recommended	   to	   proceed	   to	   sequencing	  with	   samples	   with	   <500,000	   genome	   copies	  2	  
per	  µl.	  3	  
22 Use	  the	  remaining	  material	  from	  Step	  17	  (19	  µl)	  for	  high	  throughput	  sequencing,	  up	  4	  
to	  96-­‐plex.	  (Illumina	  GAII	  or	  Hiseq,	  or	  Ion	  Torrent	  technology	  is	  suitable	  to	  generate	  a	  5	  
high	  yield	  of	  accurate	  sequence	  data.)	  	  6	  
	  7	  
23 Analyse	   the	   resulting	   sequence	   reads	   by	   mapping	   to	   a	   known	   reference	   genome	  8	  
using	  appropriate	  software	  to	  determine	  the	  depth	  and	  evenness	  of	  coverage,	  such	  9	  
as	   SMALT,	   bwa	   or	   SOAP.	   At	   least	   99%	   of	   the	   genome	   should	   have	   reads	   to	   map	  10	  
against	  it,	  with	  the	  mean	  depth	  of	  coverage	  greater	  than	  35×,	  although	  these	  values	  11	  
should	   be	   verified	   for	   each	   organism	   and	   sequencing	  method	   used.	   Calculate	   the	  12	  
coverage	   coefficient	   of	   variation	   (CV	   =	   standard	   deviation/mean).	   If	   this	   value	   is	  13	  
under	  0.5,	  coverage	  should	  be	  sufficiently	  even	  to	  allow	  confident	  base	  calling.	  If	  CV	  14	  
value	  is	  between	  0.5	  and	  1,	  manual	  checking	  of	  base	  calling	  is	  recommended.	  If	  the	  15	  
CV	   value	   is	   greater	   than	   1,	   some	   regions	   of	   the	   genome	  may	   not	   have	   sufficient	  16	  
coverage	  to	  allow	  nucleotide	  variance	  analysis.	  	  17	  
24	  Use	   the	  coverage	  values	   to	  correlate	   the	  qPCR	  results	  with	  sequencing	  success,	  18	  
such	   that	   future	   sequencing	   can	   be	   performed	   on	   samples	   with	   an	   appropriate	  19	  
number	  of	  genome	  copies	  to	  allow	  greatest	  chance	  of	  success.	  	  20	  
25	  Where	  mapping	  is	  not	  possible	  or	  advisable	  (when	  no	  referenced	  genome	  exists,	  21	  
or	  a	  large	  amount	  of	  novel	  accessory	  DNA	  is	  suspected),	  perform	  de	  novo	  assembly	  22	  
using	  SPAdes	  46	  or	  an	  equivalent	  program	  designed	  for	  use	  with	  data	  obtained	  from	  23	  
a	  sample	  which	  has	  undergone	  MDA.	  If	  required,	  align	  the	  resulting	  contigs	  against	  a	  24	  
reference	   sequence	   using	   abacas	   to	   determine	   core	   genomics	   regions,	   and	   to	  25	  
identify	  possible	  accessory	  or	  contaminant-­‐derived	  data.	  26	  
	  27	  
TIMING	  28	  
Steps	  1-­‐15,	  IMS	  of	  bacteria	  from	  complex	  samples:	  minimum	  2.5h	  29	  
Steps	  16-­‐17,	  MDA:	  2.5	  h	  30	  
Steps	   18-­‐25,	   DNA	   Quantification	   and	   Genome	   Sequencing:	   several	   days	   up	   to	   weeks,	  31	  
depending	  on	  method	  used	  32	  
	  33	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  34	  




Anticipated	  Results	  2	  
This	  protocol	  should	  yield	  complete	  bacterial	  genome	  sequences,	  derived	  through	  mapping	  3	  
and	  variant	  nucleotide	  calling	  or	  de	  novo	  assembly.	  The	  ultimate	  success	  of	  the	  protocol	  can	  4	  
only	  be	  assessed	  after	  analysis	  of	  the	  read	  data,	  although	  qPCR	  results	  can	  give	  an	  interim	  5	  
indication	  as	  to	  the	   likely	  outcome.	  Sequence	  reads	  mapping	  to	  the	  target	  bacterium	  may	  6	  
constitute	   only	   9%	   of	   the	   output	   per	   sample,	   with	   the	   remaining	   reads	   representing	  7	  
contaminating	  DNA,	  either	  human	  or	  microbial	  (Table	  2).	  This	  is	  due	  to	  the	  fact	  that	  IMS	  is	  8	  
used	   for	   enrichment	   of	   the	   target	   organism	   through	   depletion	   of	   contaminating	   DNA	   as	  9	  
opposed	   to	   absolute	   purification	   of	   the	   target.	   The	   additional	   sequencing	   read	   data	  may	  10	  
therefore	  provide	  information	  on	  the	  other	  organisms	  in	  the	  sample	  under	  analysis.	  	  11	  
The	   success	   rate	  of	   the	  protocol	   is	   likely	   to	   depend	  on	   the	  nature	   and	   the	   load	  of	   target	  12	  
organism	   in	   the	   input	   sample.	   Indeed	   repetition	   of	   the	   protocol	   on	   additional	   sample	  13	  
material	  is	  unlikely	  to	  yield	  improved	  results	  and	  is	  not	  specifically	  recommended.	  Using	  C.	  14	  
trachomatis,	  we	  achieved	  a	   success	   rate	  of	  15-­‐30%	   from	  urogenital	   samples	  and	  archived	  15	  
diagnostic	   samples	   8.	   	   Rates	   were	   considerably	   higher	   for	   more	   recent,	   viable	   samples	  16	  
archived	   after	   growth	   (100%)	   8.	   Using	   IMS-­‐MDA,	   we	   have	   also	   been	   able	   to	   generate	  17	  
complete	  genomes	  from	  older	  samples	  (up	  to	  30	  years	  old),	  which	  had	  been	  through	  several	  18	  
rounds	  of	   freeze	   thawing	  and	  were	  no	   longer	  viable,	  with	  a	  7%	  success	   rate	   (unpublished	  19	  
data).	   For	   samples	  which	   do	   not	   produce	   complete	   genome	   sequences,	   partial	   sequence	  20	  
data	  may	  still	  provide	  useful	  information	  for	  bioinformatic	  analysis.	  	  21	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Figure	  Legend	  9	  
Figure	   1.	   Schematic	   of	   the	   Immunomagnetic	   Separation	   and	   Multiple	   Displacement	  10	  
Amplification	   (IMS-­‐MDA)	   procedure.	   In	   addition	   to	   the	   procedure	   shown,	   subsequent	  11	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Table	  1.	  Troubleshooting	  table.	  1	  
Step	   Problem	   Possible	  reason	   Solution	  
2	  &	  13	  
Loss	  of	  beads	  in	  
the	  reaction	  
tube	  
Clumping	  of	  beads	  
leading	  to	  poor	  
retention	  on	  the	  
magnet.	  
	  
Ensure	  that	  Tween	  is	  added	  to	  PBST.	  
Alternative	  buffers	  can	  also	  be	  used	  
(see	  Dynabeads®	  manufacturer’s	  
instructions).	  
Take	  care	  when	  removing	  buffers	  and	  
ensure	  visually	  that	  the	  pellet	  of	  beads	  
remains	  in	  the	  tube.	  
Beads	  may	  be	  lost	  in	  
the	  tube	  or	  pipette	  tip	  
Pulse	  spin	  tube	  if	  buffer	  is	  splashed	  up	  
the	  side	  of	  tube.	  Avoid	  pipetting	  to	  mix	  







The	  sample	  and	  bead	  
mixture	  exist	  as	  
separate	  droplets	  in	  
the	  tube	  and	  do	  not	  
come	  into	  contact	  
during	  the	  incubation	  
Ensure	  that	  the	  bead-­‐containing	  buffer	  
is	  pipetted	  directly	  into	  the	  sample.	  If	  
the	  sample	  is	  viscous,	  addition	  of	  
further	  PBST	  may	  be	  advisable	  to	  a	  









Use	  concentrations	  and	  conditions	  
recommended	  for	  the	  specific	  assay.	  	  
Use	  the	  standard	  dilutions	  to	  test	  a	  
variety	  of	  conditions	  according	  to	  the	  






primary	  antibody	  may	  
have	  been	  used,	  or	  
insufficient	  quantities	  
of	  it,	  in	  step	  4.	  
This	  can	  be	  determined	  by	  retaining	  
the	  supernatant	  in	  step	  8	  and	  
performing	  qPCR	  to	  determine	  
whether	  unbound	  target	  bacterium	  
remains	  in	  the	  supernatant.	  Increased	  
amounts	  of	  antibody	  or	  an	  alternative	  
antibody	  can	  then	  be	  tested.	  
Too	  much	  
contaminating	  DNA	  or	  
MDA	  reaction	  
inhibitors	  remain	  in	  
the	  samples	  
Perform	  two	  or	  more	  additional	  
washes	  in	  PBST	  at	  step	  14.	  A	  balance	  
between	  removal	  of	  contamination	  
and	  loss	  of	  or	  damage	  to	  the	  material	  
of	  interest	  must	  be	  found.	  
Excessive	  PBST	  buffer	  
remains	  after	  IMS	  and	  
is	  transferred	  to	  the	  
MDA	  reaction	  
Ensure	  that	  as	  much	  PBST	  as	  possible	  
is	  removed	  after	  the	  final	  wash	  (step	  
15).	  Ideally	  1µl	  should	  remain,	  
although	  MDA	  has	  been	  found	  to	  be	  
effective	  even	  when	  5µl	  buffer	  is	  
added	  to	  the	  sample	  buffer	  with	  the	  
beads.	  
Poor	  sample	  quality	  
Select	  input	  (clinical)	  samples	  which	  
are	  better	  preserved	  /	  of	  higher	  
quality,	  or	  use	  a	  higher	  sample	  
volume.	  
Zlotorynski, Eytan   30.8.13 10:23
Kommentar [4]: Au,	  OK	  or	  do	  you	  prefer	  WGA?	  
Helena  30.8.13 12:48
Kommentar [5]: Fine	  by	  me!	  
